Stocktoria
Privia Health Group, Inc. PRVA
Privia Health Group, Inc. (PRVA) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.1B at a 1.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-26 | Barclays | Equal-Weight (main) |
| 2026-05-08 | Canaccord Genuity | Buy (main) |
| 2026-04-08 | Evercore ISI Group | Outperform (main) |
| 2026-03-25 | Barclays | Equal-Weight (main) |
| 2026-03-03 | Citigroup | Buy (main) |
| 2026-03-02 | Truist Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.25 |
| Retained earnings / assets | -0.114 |
| EBIT / assets | 0.025 |
| Equity / liabilities | 1.367 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PRVA | Privia Health Group, Inc. | 5/9 | 2.87 | 140.6 | +22.3% |
| PIII | P3 Health Partners Inc. | 2/9 | -10.32 | — | -2.8% |
| LFST | LifeStance Health Group, Inc. | 7/9 | 1.7 | 412.6 | +13.9% |
| PNTG | Pennant Group, Inc. | 3/9 | 1.45 | 42.2 | +36.3% |
| INNV | InnovAge Holding Corp. | 6/9 | 0.08 | — | +11.8% |
| USPH | U S PHYSICAL THERAPY INC /NV | 6/9 | 2.26 | 25.5 | +16.3% |
| WGS | GeneDx Holdings Corp. | 6/9 | -5.22 | — | +40% |
About Privia Health Group, Inc.
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
FAQ
Is PRVA financially healthy?
Privia Health Group, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PRVA pay a dividend?
No, Privia Health Group, Inc. does not currently pay a dividend.
How profitable is PRVA?
In FY2025, Privia Health Group, Inc. had a net margin of 1.1% and a return on equity of 2.9%.
What is PRVA's P/E ratio?
Privia Health Group, Inc.'s trailing price-to-earnings (P/E) ratio is about 140.6×, based on its latest annual earnings.
What is the analyst price target for PRVA?
The average Wall-Street price target for Privia Health Group, Inc. is $31.42, about 45.9% above the recent price, from 19 analysts.
Is PRVA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Privia Health Group, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 140.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.